BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology 2017;66:338-46. [DOI: 10.1016/j.jhep.2016.09.008] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 28.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Zhang Z, Yan X, Li M, Xia J, Liu Y, Chen Y, Jia B, Zhu L, Zhu C, Huang R, Wu C. Albumin-Bilirubin (ALBI) as an accurate and simple prognostic score for chronic hepatitis B-related liver cirrhosis. Digestive and Liver Disease 2019;51:1172-8. [DOI: 10.1016/j.dld.2019.01.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
2 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Reference Citation Analysis]
3 Celsa C, Giuffrida P, Giacchetto CM, Stornello C, Rancatore G, Grova M, Ricciardi MR, Rizzo S, Cammà C, Cabibbo G. Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International 2021;2:82-95. [DOI: 10.1002/lci2.38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Sreedharan A, Ustianowski AA, Agarwal K, Mutimer D, Kumada T, Toyoda H, Irving WL; HCV Research UK. Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. J Viral Hepat 2021;28:168-76. [PMID: 32978982 DOI: 10.1111/jvh.13408] [Reference Citation Analysis]
5 Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, Zou H. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol. 2018;16:208. [PMID: 30326907 DOI: 10.1186/s12957-018-1500-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
6 Kobayashi Y, Kiya Y, Sugawara T, Nishioka Y, Hashimoto M, Shindoh J. Expanded Makuuchi's criteria using estimated indocyanine green clearance rate of future liver remnant as a safety limit for maximum extent of liver resection. HPB (Oxford) 2019;21:990-7. [PMID: 30711244 DOI: 10.1016/j.hpb.2018.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Xu L, Wu J, Lu W, Yang C, Liu H. Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Transplant Proc. 2019;51:3338-3346. [PMID: 31732203 DOI: 10.1016/j.transproceed.2019.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Adhoute X, Pénaranda G, Raoul J, Pietri O, Bronowicki J, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. European Journal of Gastroenterology & Hepatology 2019;31:1414-23. [DOI: 10.1097/meg.0000000000001420] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Bernardi N, Chedid MF, Grezzana-filho TJM, Chedid AD, Pinto MA, Leipnitz I, Prediger JE, Prediger C, Backes AN, Hammes TO, Guerra LT, de Araujo A, Alvares-da-silva MR, Kruel CRP. Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation. Dig Dis Sci 2019;64:1695-704. [DOI: 10.1007/s10620-019-5456-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
10 Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, Neumann-Haefelin C, Brunner TB, Gkika E, Maruschke L, Thimme R, Schultheiss M. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol 2017;17:98. [PMID: 28797231 DOI: 10.1186/s12876-017-0656-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
11 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
12 Chen GX, Qi CY, Hu WJ, Wang XH, Hua YP, Kuang M, Peng BG, Li SQ. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma. BMC Cancer 2020;20:487. [PMID: 32471389 DOI: 10.1186/s12885-020-06980-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Dai HT, Chen B, Tang KY, Zhang GY, Wen CY, Xiang XH, Yang JY, Guo Y, Lin R, Huang YH. Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Gastrointest Oncol 2021;12:1141-51. [PMID: 34295563 DOI: 10.21037/jgo-21-226] [Reference Citation Analysis]
14 Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, Toyoda H, Zhou MT. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. Clin Chim Acta 2018;485:187-94. [PMID: 29908940 DOI: 10.1016/j.cca.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
16 Lu L, Zheng P, Wu Z, Chen X. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol 2021;11:618937. [PMID: 34778022 DOI: 10.3389/fonc.2021.618937] [Reference Citation Analysis]
17 Kolamunnage-Dona R, Berhane S, Potts H, Williams EH, Tanner J, Janowitz T, Hoare M, Johnson P. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 2021:S0168-8278(21)00350-0. [PMID: 34052255 DOI: 10.1016/j.jhep.2021.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 He J, Sun H, Li F, Yang H, Lou M, Wang S, Wu C. Efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real-world study. Hepatol Res 2021;51:1153-63. [PMID: 34492152 DOI: 10.1111/hepr.13708] [Reference Citation Analysis]
19 Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018;8:10434. [PMID: 29992975 DOI: 10.1038/s41598-018-28650-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
20 Oh IS, Sinn DH, Kang TW, Lee MW, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Dig Dis Sci. 2017;62:3235-3242. [PMID: 28983724 DOI: 10.1007/s10620-017-4775-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
21 Chen HY, Kee KM, Lu SN, Wang JH, Chen CH, Hung CH, Yen YH, Kuo YH. Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. J Formos Med Assoc 2021:S0929-6646(21)00315-6. [PMID: 34303584 DOI: 10.1016/j.jfma.2021.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Tsilimigras DI, Hyer JM, Moris D, Sahara K, Bagante F, Guglielmi A, Aldrighetti L, Alexandrescu S, Marques HP, Shen F, Koerkamp BG, Endo I, Pawlik TM; other members of the International Intrahepatic Cholangiocarcinoma Study Group. Prognostic utility of albumin‐bilirubin grade for short‐ and long‐term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi‐institutional analysis of 706 patients. J Surg Oncol 2019. [DOI: 10.1002/jso.25486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
23 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
24 Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer 2020;9:308-25. [PMID: 32647633 DOI: 10.1159/000505692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol 2022;60:81-107. [PMID: 35042249 DOI: 10.1055/a-1589-7520] [Reference Citation Analysis]
27 Mishra G, Majeed A, Dev A, Eslick GD, Pinato DJ, Izumoto H, Hiraoka A, Huo T, Liu P, Johnson PJ, Roberts SK. Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00832-0] [Reference Citation Analysis]
28 Ronald J, Wang Q, Choi S, Suhocki P, Hall M, Smith T, Kim C. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. Diagnostic and Interventional Imaging 2018;99:163-8. [DOI: 10.1016/j.diii.2017.10.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
29 Chedid MF, Picon RV, Chedid AD. ALBI and PALBI: Novel Scores for Outcome Prediction of Cirrhotic Outpatients Awaiting Liver Transplantation. Ann Hepatol. 2018;17:906-907. [PMID: 30600306 DOI: 10.5604/01.3001.0012.7190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Ah Hwang J, Wook Kang T, Hye Min J, Kon Kim Y, Hyun Kim S, Hyun Sinn D, Kim K. Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110328] [Reference Citation Analysis]
31 Zhang ZQ, Yang B, Zou H, Xiong L, Miao XY, Wen Y, Zhou JJ. ALBI/ST ratio versus FIB-4 and APRI as a predictor of posthepatectomy liver failure in hepatocellular carcinoma patients. Medicine (Baltimore) 2019;98:e15168. [PMID: 30985698 DOI: 10.1097/MD.0000000000015168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) score: The current status. The Surgeon 2020;18:178-86. [DOI: 10.1016/j.surge.2019.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 2020;12:E1862. [PMID: 32664319 DOI: 10.3390/cancers12071862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
34 Morise Z, Aldrighetti L, Belli G, Ratti F, Cheung TT, Lo CM, Tanaka S, Kubo S, Okamura Y, Uesaka K, Monden K, Sadamori H, Hashida K, Kawamoto K, Gotohda N, Chen K, Kanazawa A, Takeda Y, Ohmura Y, Ueno M, Ogura T, Suh KS, Kato Y, Sugioka A, Belli A, Nitta H, Yasunaga M, Cherqui D, Halim NA, Laurent A, Kaneko H, Otsuka Y, Kim KH, Cho HD, Lin CC, Ome Y, Seyama Y, Troisi RI, Berardi G, Rotellar F, Wilson GC, Geller DA, Soubrane O, Yoh T, Kaizu T, Kumamoto Y, Han HS, Ekmekcigil E, Dagher I, Fuks D, Gayet B, Buell JF, Ciria R, Briceno J, O'Rourke N, Lewin J, Edwin B, Shinoda M, Abe Y, Hilal MA, Alzoubi M, Tanabe M, Wakabayashi G. An International Retrospective Observational Study of Liver Functional Deterioration after Repeat Liver Resection for Patients with Hepatocellular Carcinoma. Cancers (Basel) 2022;14:2598. [PMID: 35681578 DOI: 10.3390/cancers14112598] [Reference Citation Analysis]
35 Li JP, Zhao S, Jiang HJ, Jiang H, Zhang LH, Shi ZX, Fan TT, Wang S. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00135-7. [PMID: 35729000 DOI: 10.1016/j.hbpd.2022.06.003] [Reference Citation Analysis]
36 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
37 Chen X, Zhao Y, Chen W, Shao X, Huang Z, Granito A. Lactate and Bilirubin Index: A New Indicator to Predict Critically Ill Cirrhotic Patients’ Prognosis. Canadian Journal of Gastroenterology and Hepatology 2021;2021:1-7. [DOI: 10.1155/2021/6624177] [Reference Citation Analysis]
38 Han S, Wang C, Tong F, Li Y, Li Z, Sun Z, Sun Z. Prognostic impact of albumin-bilirubin score on the prediction of in-hospital mortality in patients with heart failure: a retrospective cohort study. BMJ Open 2022;12:e049325. [PMID: 34983753 DOI: 10.1136/bmjopen-2021-049325] [Reference Citation Analysis]
39 Li K, Jiang F, Aizpuru M, Larson EL, Xie X, Zhou R, Xiang B. Successful management and technical aspects of major liver resection in children: A retrospective cohort study. Medicine (Baltimore) 2021;100:e24420. [PMID: 33578534 DOI: 10.1097/MD.0000000000024420] [Reference Citation Analysis]
40 Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. J Clin Oncol 2019;37:296-304. [PMID: 30562130 DOI: 10.1200/JCO.18.00885] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
41 Amisaki M, Uchinaka E, Morimoto M, Tokuyasu N, Sakamoto T, Honjo S, Saito H, Fujiwara Y. Post-operative albumin-bilirubin grade predicts long-term outcomes among Child-Pugh grade A patients with hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int. 2018;17:502-509. [PMID: 30077606 DOI: 10.1016/j.hbpd.2018.07.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
42 Carr BI, Guerra V. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients. Int J Biol Markers. 2017;32:e391-e396. [PMID: 28862714 DOI: 10.5301/ijbm.5000300] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
43 Teng W, Jeng WJ, Yang HI, Chen WT, Hsieh YC, Huang CH, Lin CC, Lin CY, Lin SM, Sheen IS. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2019;12:E23. [PMID: 31861706 DOI: 10.3390/cancers12010023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
46 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
47 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
48 Giannini EG. Editorial: a step forward in refining prognostication for patients with HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther 2018;47:133-4. [PMID: 29226414 DOI: 10.1111/apt.14374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One 2019;14:e0216173. [PMID: 31048923 DOI: 10.1371/journal.pone.0216173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
50 Kotoh Y, Saeki I, Yamasaki T, Sasaki R, Tanabe N, Oono T, Maeda M, Hidaka I, Ishikawa T, Takami T, Sakaida I. Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma. Clin Nutr 2021;40:3585-91. [PMID: 33386180 DOI: 10.1016/j.clnu.2020.12.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Geschwind JH, Hochster HS. Tools from the World of Artificial Intelligence in Interventional Oncology: Be Careful What You Wish For. J Vasc Interv Radiol 2019;30:339-41. [PMID: 30819474 DOI: 10.1016/j.jvir.2019.01.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med 2020;8:537. [PMID: 32411760 DOI: 10.21037/atm.2020.02.114] [Reference Citation Analysis]
54 Lin P, Teng W, Jeng W, Chen W, Hsieh Y, Huang C, Lui K, Hung C, Wang C, Chai P, Lin C, Lin C, Lin S, Sheen I. Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. Diagnostics 2022;12:665. [DOI: 10.3390/diagnostics12030665] [Reference Citation Analysis]
55 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 82.0] [Reference Citation Analysis]
56 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Orimo T, Kamiyama T, Kamachi H, Shimada S, Nagatsu A, Asahi Y, Sakamoto Y, Abo D, Taketomi A. Predictive value of gadoxetic acid enhanced magnetic resonance imaging for posthepatectomy liver failure after a major hepatectomy. J Hepatobiliary Pancreat Sci 2020;27:531-40. [DOI: 10.1002/jhbp.769] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
58 Shi JY, Sun LY, Quan B, Xing H, Li C, Liang L, Pawlik TM, Zhou YH, Wang H, Gu WM, Chen TH, Lau WY, Shen F, Wang NY, Yang T. A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101534. [PMID: 33067168 DOI: 10.1016/j.clinre.2020.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
59 Hiraoka A, Tanizawa Y, Huang YJ, Cai Z, Sakaguchi S. Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database. Drugs Real World Outcomes 2021;8:301-14. [PMID: 33792850 DOI: 10.1007/s40801-021-00245-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Mähringer-kunz A, Kloeckner R, Pitton MB, Düber C, Schmidtmann I, Galle PR, Koch S, Weinmann A. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2017;40:1017-25. [DOI: 10.1007/s00270-017-1606-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
61 Kaewdech A, Sripongpun P, Cheewasereechon N, Jandee S, Chamroonkul N, Piratvisuth T. Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. Clin Transl Gastroenterol 2021;12:e00310. [PMID: 33605612 DOI: 10.14309/ctg.0000000000000310] [Reference Citation Analysis]
62 Ni J, Fang Z, Sun H, An C, Huang Z, Zhang T, Jiang X, Chen Y, Xu L, Huang J. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Eur Radiol 2020;30:2377-90. [DOI: 10.1007/s00330-019-06438-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
63 Zou H, Wen Y, Yuan K, Miao X, Xiong L, Liu K. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int 2018;38:494-502. [DOI: 10.1111/liv.13514] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
64 Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer 2020;9:518-28. [PMID: 33083278 DOI: 10.1159/000507933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Lo CH, Liu MY, Lee MS, Yang JF, Jen YM, Lin CS, Chao HL, Shen PC, Huang WY. Comparison Between Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Assessing the Prognosis of Hepatocellular Carcinoma After Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017;99:145-152. [PMID: 28816140 DOI: 10.1016/j.ijrobp.2017.04.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
66 Wang JC, Hou JY, Chen JC, Xiang CL, Mao XH, Yang B, Li Q, Liu QB, Chen J, Ye ZW, Peng W, Sun XQ, Chen MS, Zhou QF, Zhang YJ. Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. Eur J Cancer 2021;155:85-96. [PMID: 34371445 DOI: 10.1016/j.ejca.2021.07.009] [Reference Citation Analysis]
67 Gan W, Zhang MX, Wang JX, Fu YP, Huang JL, Yi Y, Jing CY, Fan J, Zhou J, Qiu SJ. Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child-Pugh I who underwent curative resection: a prognostic nomogram study. Cancer Manag Res 2018;10:5383-94. [PMID: 30464634 DOI: 10.2147/CMAR.S176317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
68 Chen PH, Hsieh WY, Su CW, Hou MC, Wang YP, Hsin IF, Yang TC, Liao WC, Lin HC, Lee FY, Wu JC. Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices. Gastrointest Endosc. 2018;88:230-239.e2. [PMID: 29317268 DOI: 10.1016/j.gie.2017.12.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
69 Zhang M, Chua MS, Hu J, Li H, Zhang S, Wu L, Han B. High Inflammatory Factor Grading Predicts Poor Disease-Free Survival in AJCC Stage I-II Hepatocellular Carcinoma Patients After R0 Resection. Cancer Manag Res 2019;11:10623-32. [PMID: 31908534 DOI: 10.2147/CMAR.S230386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Pirisi M, Leutner M, Romito R, Gaia S. Novel Calculators for Risk Stratification in Hepatocellular Carcinoma: A Concise Review. J Clin Gastroenterol 2020;54:789-94. [PMID: 32773489 DOI: 10.1097/MCG.0000000000001406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020;72:198-212. [PMID: 31698504 DOI: 10.1002/hep.31022] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 26.0] [Reference Citation Analysis]
72 Ni J, Fang Z, An C, Sun H, Huang Z, Zhang T, Jiang X, Chen Y, Xu L, Huang J. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. International Journal of Hyperthermia 2019;36:840-52. [DOI: 10.1080/02656736.2019.1646927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Hansmann J, Evers MJ, Bui JT, Lokken RP, Lipnik AJ, Gaba RC, Ray CE. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2017;28:1224-1231.e2. [PMID: 28688815 DOI: 10.1016/j.jvir.2017.05.020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
74 Delhaye C, Hendlisz A, Vouche M. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. Curr Opin Oncol 2019;31:339-45. [PMID: 30896451 DOI: 10.1097/CCO.0000000000000539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World J Gastroenterol 2020; 26(33): 5022-5049 [PMID: 32952347 DOI: 10.3748/wjg.v26.i33.5022] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Huo TI, Liu PH, Hsu CY. Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade. J Hepatol 2019;70:808. [PMID: 30678994 DOI: 10.1016/j.jhep.2018.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Chan AW, Berhane S, Cucchetti A, Johnson PJ. Reply to: Correspondence concerning “Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection”. Journal of Hepatology 2019;70:573-4. [DOI: 10.1016/j.jhep.2018.11.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 2020;8:238. [PMID: 32309385 DOI: 10.21037/atm.2019.12.157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
79 Yu JI, Park HC, Yoo GS, Choi C, Choi MS, Nam H, Baek SY, Park M. Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma. Sci Rep 2021;11:2614. [PMID: 33510378 DOI: 10.1038/s41598-021-82177-5] [Reference Citation Analysis]
80 Negri F, Missale G, Antoni AD, Porta C. Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Transl Oncol 2021;14:101153. [PMID: 34144349 DOI: 10.1016/j.tranon.2021.101153] [Reference Citation Analysis]
81 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
82 Ke MY, Wu XN, Zhang Y, Wang S, Lv Y, Dong J. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma. J Transl Med 2019;17:140. [PMID: 31046807 DOI: 10.1186/s12967-019-1889-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
83 Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu A, Brunner TB. The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol 2018;194:403-13. [DOI: 10.1007/s00066-017-1256-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
84 Zhao Z, Zheng Z, Huang J, Wang J, Peng T, Lin Y, Jian Z. Expression of ALG3 in Hepatocellular Carcinoma and Its Clinical Implication. Front Mol Biosci 2022;9:816102. [DOI: 10.3389/fmolb.2022.816102] [Reference Citation Analysis]
85 Zhong BY, Wang WS, Shen J, Du H, Zhang S, Li WC, Yin Y, Yang J, Ni CF, Zhu XL. Single-Centre Retrospective Training Cohort Using Artificial Intelligence for Prognostic Prediction of Encephalopathy, Mortality, and Liver Dysfunction after Early TIPS Creation. Cardiovasc Intervent Radiol 2021;44:1597-608. [PMID: 34240232 DOI: 10.1007/s00270-021-02907-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Hansmann J, Ray CE Jr. Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Semin Intervent Radiol 2017;34:213-9. [PMID: 28579689 DOI: 10.1055/s-0037-1602757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Tsai PH, Chou SJ, Lee RC, Hou MC, Huo TI. Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res 2021. [PMID: 34038019 DOI: 10.1111/hepr.13671] [Reference Citation Analysis]
88 Lu LH, Wei-Wei, Kan A, Jie-Mei, Ling YH, Li SH, Guo RP. Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma. Dis Markers 2020;2020:4269460. [PMID: 32695241 DOI: 10.1155/2020/4269460] [Reference Citation Analysis]
89 Pinato DJ, Yen C, Sharma R. Reply to: ‘Validating the ALBI grade: Its current and future use in HCC prognostication’. Journal of Hepatology 2017;66:663-4. [DOI: 10.1016/j.jhep.2016.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
90 Lawal G, Xiao Y, Rahnemai-Azar AA, Tsilimigras DI, Kuang M, Bakopoulos A, Pawlik TM. The Immunology of Hepatocellular Carcinoma. Vaccines (Basel) 2021;9:1184. [PMID: 34696292 DOI: 10.3390/vaccines9101184] [Reference Citation Analysis]
91 Takada K, Takamori S, Shimokawa M, Toyokawa G, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy. ESMO Open 2021;7:100348. [PMID: 34942439 DOI: 10.1016/j.esmoop.2021.100348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, Mukherjee SK, Thursz M, Wong CN, Sharma R, Rimassa L. Immune-based therapies for hepatocellular carcinoma. Oncogene 2020;39:3620-37. [PMID: 32157213 DOI: 10.1038/s41388-020-1249-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
93 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
94 Guha IN, Harris R, Berhane S, Dillon A, Coffey L, James MW, Cucchetti A, Harman DJ, Aithal GP, Elshaarawy O, Waked I, Stewart S, Johnson PJ. Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. Clin Gastroenterol Hepatol 2019;17:2330-2338.e1. [PMID: 30716478 DOI: 10.1016/j.cgh.2019.01.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
95 Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, Rewisha E, Waked I. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol 2019; 11(6): 542-552 [PMID: 31293722 DOI: 10.4254/wjh.v11.i6.542] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
96 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Reference Citation Analysis]
97 Guo G, Lei Z, Tang X, Ma W, Si A, Yang P, Li Q, Geng Z, Zhou J, Cheng Z. External Validation of Six Liver Functional Reserve Models to predict Posthepatectomy Liver Failure after Major Resection for Hepatocellular Carcinoma. J Cancer 2021;12:5260-7. [PMID: 34335942 DOI: 10.7150/jca.58726] [Reference Citation Analysis]
98 Palmer DH, Hawkins NS, Vilgrain V, Pereira H, Chatellier G, Ross PJ. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol. 2020;16:4315-4325. [PMID: 31797680 DOI: 10.2217/fon-2019-0658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
99 Zhang H, Liu F, Wen N, Li B, Wei Y. Patterns, timing, and predictors of recurrence after laparoscopic liver resection for hepatocellular carcinoma: results from a high-volume HPB center. Surg Endosc 2021. [PMID: 33620568 DOI: 10.1007/s00464-021-08390-5] [Reference Citation Analysis]
100 Deng M, Li S, Wang Q, Zhao R, Zou J, Lin W, Mei J, Wei W, Guo R. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med 2022;54:803-11. [PMID: 35272564 DOI: 10.1080/07853890.2022.2048416] [Reference Citation Analysis]
101 Zhang CH, Ni XC, Chen BY, Qiu SJ, Zhu YM, Luo M. Combined preoperative albumin-bilirubin (ALBI) and serum γ-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection.J Cancer. 2019;10:4836-4845. [PMID: 31598154 DOI: 10.7150/jca.33877] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
102 Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HL, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology 2020;73:1368-78. [DOI: 10.1016/j.jhep.2020.07.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
103 Wang C, Wang MD, Cheng P, Huang H, Dong W, Zhang WW, Li PP, Lin C, Pan ZY, Wu MC, Zhou WP. Hepatitis B virus X protein promotes the stem-like properties of OV6+ cancer cells in hepatocellular carcinoma. Cell Death Dis 2017;8:e2560. [PMID: 28102846 DOI: 10.1038/cddis.2016.493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
104 Grąt M, Krasnodębski M, Krawczyk M, Stypułkowski J, Morawski M, Wasilewicz M, Lewandowski Z, Grąt K, Patkowski W, Zieniewicz K. Extremes of Liver Transplantation for Hepatocellular Carcinoma. J Clin Med 2019;8:E787. [PMID: 31163668 DOI: 10.3390/jcm8060787] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Pereyra D, Rumpf B, Ammann M, Perrodin SF, Tamandl D, Haselmann C, Stift J, Brostjan C, Laengle F, Beldi G, Gruenberger T, Starlinger P. The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. Ann Surg Oncol 2019;26:791-9. [PMID: 30617869 DOI: 10.1245/s10434-018-07125-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
106 Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer 2018;7:359-71. [PMID: 30488024 DOI: 10.1159/000487858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
107 Ali R, Yang Y, Antkowiak M, Gabr A, Mora R, Abouchaleh N, Al Asadi A, Kulik L, Ganger D, Abecassis M, Kataraya N, Mulcahy M, Benson A, Mahalingam D, Thornburg B, Mouli S, Lewandowski RJ, Salem R, Riaz A. Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. Cardiovasc Intervent Radiol 2019;42:700-11. [DOI: 10.1007/s00270-019-02191-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
108 Ni JY, An C, Zhang TQ, Huang ZM, Jiang XY, Huang JH. Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma. Int J Hyperthermia 2019;36:328-36. [PMID: 30689465 DOI: 10.1080/02656736.2019.1567834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
109 Jeliazkova P, Umgelter A, Braren R, Kaissis G, Mustafa M, Einwächter H. Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study. Eur J Gastroenterol Hepatol 2020;32:1036-41. [PMID: 31851090 DOI: 10.1097/MEG.0000000000001625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
110 Pinato DJ, Bräu N, Bower M. Editorial: a step forward in refining prognostication for patients with HIV-associated hepatocellular carcinoma-Authors' reply. Aliment Pharmacol Ther 2018;47:134-5. [PMID: 29226401 DOI: 10.1111/apt.14394] [Reference Citation Analysis]
111 Matsushima H, Takami Y, Ryu T, Yoshitomi M, Tateishi M, Wada Y, Saitsu H. Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade. J Gastrointest Surg 2018;22:1230-8. [DOI: 10.1007/s11605-018-3745-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
112 Sherman M. The third year. JHEP Rep 2021;3:100259. [PMID: 33898957 DOI: 10.1016/j.jhepr.2021.100259] [Reference Citation Analysis]
113 Su TS, Yang HM, Zhou Y, Huang Y, Liang P, Cheng T, Chen L, Li LQ, Liang SX. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. Radiat Oncol. 2019;14:50. [PMID: 30917853 DOI: 10.1186/s13014-019-1251-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
114 Geng L, Zong R, Shi Y, Xu K. Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32:769-778. [PMID: 31834053 DOI: 10.1097/meg.0000000000001618] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
115 Li JD, Xu XF, Han J, Wu H, Xing H, Li C, Yu JJ, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Lau WY, Wu MC, Shen F, Yang T. Preoperative prealbumin level as an independent predictor of long-term prognosis after liver resection for hepatocellular carcinoma: a multi-institutional study. HPB (Oxford). 2019;21:157-166. [PMID: 30082212 DOI: 10.1016/j.hpb.2018.06.1803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
116 Su C, Fang K, Lee R, Liu C, Chen P, Lee P, Kao W, Huang Y, Huo T, Hou M, Lin H, Wu J. Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association 2020;119:610-20. [DOI: 10.1016/j.jfma.2019.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Zhang J, Wang T, Xu L, Wang P, Zhang M, Xu M. Development and validation of a prognostic model based on the albumin-to-fibrinogen ratio (AFR) and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in hepatocellular carcinoma patients. Clin Chim Acta 2020;511:107-16. [PMID: 33035501 DOI: 10.1016/j.cca.2020.09.038] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 He MK, Liang RB, Zhao Y, Xu YJ, Chen HW, Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol 2021;13:17588359211002720. [PMID: 33854567 DOI: 10.1177/17588359211002720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
119 Chen W, Zhang Z, Fang X, Xiong L, Wen Y, Zhou J, Kong F, Zou H. Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion. Medicine (Baltimore) 2021;100:e26265. [PMID: 34128857 DOI: 10.1097/MD.0000000000026265] [Reference Citation Analysis]
120 Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer. 2018;7:335-358. [PMID: 30488023 DOI: 10.1159/000487407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
121 Yang Y, Ye F, Xin Y, Wang Y, Li X, Feng D, Chen Y, Zhou X. Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. J Gastrointest Oncol 2020;11:1024-39. [PMID: 33209495 DOI: 10.21037/jgo-20-225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
122 Nguyen TTH, Nguyen VH, Nguyen VH, Nguyen TL, Le VQ. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam. Cancer Control. 2019;26:1073274819865269. [PMID: 31364390 DOI: 10.1177/1073274819865269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019;39:1704-1712. [PMID: 31319016 DOI: 10.1111/liv.14194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
124 Rimini M, Rovesti G, Casadei-Gardini A. Child Pugh and ALBI grade: past, present or future? Ann Transl Med 2020;8:1044. [PMID: 33145263 DOI: 10.21037/atm-20-3709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
126 Li C, Zhang XY, Peng W, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Xu MQ, Chen LP. Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection. Medicine (Baltimore). 2018;97:e11599. [PMID: 30024565 DOI: 10.1097/md.0000000000011599] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
127 Liu Y, Cheng C, Zhou H, Hu S, Wang H, Xie Q, Lei L, Wang P, Liu G, Hu H. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization. Bull Cancer 2021:S0007-4551(21)00241-1. [PMID: 34247763 DOI: 10.1016/j.bulcan.2021.04.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
129 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
130 Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Dig Dis Sci. 2018;63:1062-1071. [PMID: 29442276 DOI: 10.1007/s10620-018-4934-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
131 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
132 Carling U, Røsok B, Line PD, Dorenberg EJ. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma. Acta Radiol 2019;60:702-9. [PMID: 30205701 DOI: 10.1177/0284185118799519] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
133 Ye L, Liang R, Zhang J, Chen C, Chen X, Zhang Y, Wang G, Yang Y, Chen G. Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy. Ann Transl Med. 2019;7:367. [PMID: 31555681 DOI: 10.21037/atm.2019.06.01] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
134 Sharma R, Motedayen Aval L. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:652007. [PMID: 33790915 DOI: 10.3389/fimmu.2021.652007] [Reference Citation Analysis]
135 Zhong BY, Ni CF, Ji JS, Yin GW, Chen L, Zhu HD, Guo JH, He SC, Deng G, Zhang Q, Li PC, Yu H, Song JJ, Teng GJ. Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. J Vasc Interv Radiol 2019;30:330-8. [PMID: 30819473 DOI: 10.1016/j.jvir.2018.08.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
136 Liu X, Wang X, Yu L, Hou Y, Jiang Y, Wang X, Han J, Yang Z. A Novel Prognostic Score Based on Artificial Intelligence in Hepatocellular Carcinoma: A Long-Term Follow-Up Analysis. Front Oncol 2022;12:817853. [DOI: 10.3389/fonc.2022.817853] [Reference Citation Analysis]
137 Huang Q, Zeng Q, Long Y, Tan L, Zheng R, Xu E, Li K. Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma - A prospective randomized controlled trial. Int J Hyperthermia. 2019;36:1207-1215. [PMID: 31813295 DOI: 10.1080/02656736.2019.1687945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
138 Lu LH, Zhang YF, Mu-Yan C, Kan A, Zhong XP, Mei J, Ling YH, Li SH, Shi M, Wei W, Guo RP. Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Dig Liver Dis. 2019;51:1430-1437. [PMID: 31054962 DOI: 10.1016/j.dld.2019.04.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
139 Gan W, Huang JL, Zhang MX, Fu YP, Yi Y, Jing CY, Fan J, Zhou J, Qiu SJ. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. J Surg Oncol 2018;117:1540-7. [PMID: 29572833 DOI: 10.1002/jso.25046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
140 D'Alessio A, Prete MG, Cammarota A, Personeni N, Rimassa L. The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. J Hepatocell Carcinoma 2021;8:177-91. [PMID: 33824862 DOI: 10.2147/JHC.S268310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Chi CT, Lee IC, Lee RC, Hung YW, Su CW, Hou MC, Chao Y, Huang YH. Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancers (Basel) 2021;13:4325. [PMID: 34503135 DOI: 10.3390/cancers13174325] [Reference Citation Analysis]
142 Wang D, Huang S, Xu G, Wu S, Liu Z, Xu L, Hu B, Hou J. Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension. Front Cardiovasc Med 2022;9:897040. [DOI: 10.3389/fcvm.2022.897040] [Reference Citation Analysis]
143 Luo J, Li M, Wu C, Zhu D, Wang H, Huang M, Jiang Z. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. Eur J Gastroenterol Hepatol 2021;33:436-42. [PMID: 32398493 DOI: 10.1097/MEG.0000000000001750] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Chan AWH, Leung HHW, Chong CCN, Chan SL. Validating the ALBI grade: Its current and future use in HCC prognostication. J Hepatol 2017;66:661-3. [PMID: 27890792 DOI: 10.1016/j.jhep.2016.10.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
145 Zou H, Yang X, Li QL, Zhou QX, Xiong L, Wen Y. A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients. Dig Dis 2018;36:236-43. [PMID: 29495004 DOI: 10.1159/000486590] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
146 Dong ZR, Zou J, Sun D, Shi GM, Ke AW, Cai JB, Sun HC, Qiu SJ, Li T, Zhou J, Zhi XT, Fan J. Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. J Cancer. 2017;8:3862-3867. [PMID: 29151974 DOI: 10.7150/jca.21313] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
147 Carr BI, Guerra V, Donghia R, Yilmaz S. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes. Ann Med Surg (Lond) 2021;66:102458. [PMID: 34141428 DOI: 10.1016/j.amsu.2021.102458] [Reference Citation Analysis]
148 Zhu C, Wang X, Yang X, Sun J, Pan B, Zhang W, Chen X, Shen X. Preoperative Albumin-Bilirubin Grade as a Prognostic Predictor in Colorectal Cancer Patients Who Undergo Radical Resection. Cancer Manag Res 2020;12:12363-74. [PMID: 33293863 DOI: 10.2147/CMAR.S285212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1003] [Article Influence: 395.0] [Reference Citation Analysis]
150 Shi JY, Wang NY. Is ALPlat criterion justified for predicting posthepatectomy liver failure? Surgery 2020;168:1180. [PMID: 32682506 DOI: 10.1016/j.surg.2020.05.034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Bai Y, Lian Y, Chen X, Wu J, Lai J, Qiu F, Zhou S, Zhu Z, Tian Y, Wang Y, Yang Y, Yan M. Immunohistochemical Signature Add Prognostic Value in Patients With Early and Intermediate Hepatocellular Carcinoma Underwent Curative Liver Resection. Front Oncol 2020;10:616263. [PMID: 33585243 DOI: 10.3389/fonc.2020.616263] [Reference Citation Analysis]
152 Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, Kudo M, Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X. Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer 2021;10:38-51. [PMID: 33708638 DOI: 10.1159/000512028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
153 Yamamoto M, Kobayashi T, Kuroda S, Hamaoka M, Okimoto S, Honmyo N, Yamaguchi M, Ohdan H. Verification of inflammation-based prognostic marker as a prognostic indicator in hepatocellular carcinoma. Ann Gastroenterol Surg 2019;3:667-75. [PMID: 31788655 DOI: 10.1002/ags3.12286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
154 Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, Fritsch R, Brass V, Maruschke L, Neeff HP, Lang SA, Nestle U, Grosu A, Brunner TB. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol 2019;195:246-53. [DOI: 10.1007/s00066-018-1385-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
155 Li H, Li J, Wang J, Liu H, Cai B, Wang G, Wu H. Assessment of Liver Function for Evaluation of Long-Term Outcomes of Intrahepatic Cholangiocarcinoma: A Multi-Institutional Analysis of 620 Patients. Front Oncol 2020;10:525. [PMID: 32411593 DOI: 10.3389/fonc.2020.00525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
156 Kim CG, Lee HW, Choi HJ, Lee JI, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim HS, Kim KH, Choi SJ, Kim Y, Lee KS, Kim GM, Kim MD, Won JY, Lee DY, Kim BK. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med. 2019;8:5023-5032. [PMID: 31290618 DOI: 10.1002/cam4.2417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
157 Huo TI, Liu PH, Hsu CY. ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Is It Sufficient? Liver Cancer 2017;6:375-6. [PMID: 29234640 DOI: 10.1159/000481211] [Reference Citation Analysis]
158 Li JD, Diao YK, Li J, Wu H, Sun LY, Gu WM, Wang H, Chen TH, Zeng YY, Zhou YH, Wang Y, Zhang YM, Liang YJ, Lau WY, Li C, Liang L, Wang MD, Zhang CW, Shen F, Shao CH, Yang T. Association between preoperative prealbumin level and postoperative mortality and morbidity after hepatic resection for hepatocellular carcinoma: A multicenter study from a HBV-endemic area. Am J Surg 2021;221:1024-32. [PMID: 32951853 DOI: 10.1016/j.amjsurg.2020.08.036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
159 Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res 2021;149:257-94. [PMID: 33579425 DOI: 10.1016/bs.acr.2020.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
160 Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G, Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L, Mazzella G, Brillanti S, Andreone P. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease 2019;51:681-8. [DOI: 10.1016/j.dld.2018.09.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
161 Huo TI, Ho SY, Liu PH. Is computed tomography-enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma? J Gastroenterol Hepatol 2020;35:2289. [PMID: 32720401 DOI: 10.1111/jgh.15203] [Reference Citation Analysis]
162 D'Avola D, Granito A, de la Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma. J Hepatol 2021:S0168-8278(21)02185-1. [PMID: 34793869 DOI: 10.1016/j.jhep.2021.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
163 Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N; Liver Cancer in HIV Study Group. The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Aliment Pharmacol Ther 2018;47:95-103. [PMID: 29034998 DOI: 10.1111/apt.14356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
164 Chen HY, Lu SN, Hung CH, Wang JH, Chen CH, Yen YH, Kuo YH, Kee KM. Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. PLoS One 2020;15:e0242113. [PMID: 33170894 DOI: 10.1371/journal.pone.0242113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Li S, Zhang X, Li Q, Lv B, Zhang Y, Jia J, Yue X, Lu W. Development and validation of the nomogram based on INR and eGFR for estimation of mortality in patients with acute-on-chronic hepatitis B liver failure. BMC Gastroenterol 2021;21:474. [PMID: 34911462 DOI: 10.1186/s12876-021-02054-3] [Reference Citation Analysis]
166 Taylor AC, Maddirela D, White SB. Role of Radioembolization for Biliary Tract and Primary Liver Cancer. Surgical Oncology Clinics of North America 2019;28:731-43. [DOI: 10.1016/j.soc.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Liu X, Hou Y, Wang X, Yu L, Wang X, Jiang L, Yang Z. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int 2020;14:567-76. [DOI: 10.1007/s12072-020-10046-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
168 Giannini EG. Improving prognosis of patients with very early hepatocellular carcinoma: How far are we going? Dig Liver Dis 2021;53:143-5. [PMID: 33257141 DOI: 10.1016/j.dld.2020.11.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Eilard MS, Naredi P, Helmersson M, Hemmingsson O, Isaksson B, Lindell G, Sandström P, Strömberg C, Rizell M. Survival and prognostic factors after transplantation, resection and ablation in a national cohort of early hepatocellular carcinoma. HPB 2021;23:394-403. [DOI: 10.1016/j.hpb.2020.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, Tanaka J. Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Sci 2017;108:2438-44. [PMID: 28945309 DOI: 10.1111/cas.13406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
171 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
172 Eguchi A, Hasegawa H, Iwasa M, Tamai Y, Ohata K, Oikawa T, Sugaya T, Takei Y. Serum Liver-Type Fatty Acid-Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma. Hepatol Commun. 2019;3:825-837. [PMID: 31168516 DOI: 10.1002/hep4.1350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
173 Lin X, Gao F, Wu X, Cai W, Chen X, Huang Z. Efficacy of albumin-bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2021;33:862-71. [PMID: 32541240 DOI: 10.1097/MEG.0000000000001801] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
174 Cai XR, Chen ZH, Liu MM, Lin JX, Zhang XP, Chen J, Lin Q, Ma XK, Wen JY, Xie SD, Wu XY, Dong M. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer. 2018;9:2380-2388. [PMID: 30026834 DOI: 10.7150/jca.22925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
175 Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer 2020;8:e000726. [PMID: 33028690 DOI: 10.1136/jitc-2020-000726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
176 Zhu C, Wang X, Chen S, Yang X, Sun J, Pan B, Zhang W, Chen X, Huang Y. Efficacy of the Preoperative Albumin-Bilirubin Grade for Predicting Survival and Outcomes of Postoperative Chemotherapy for Advanced Gastric Cancer. Cancer Manag Res 2020;12:11921-32. [PMID: 33244269 DOI: 10.2147/CMAR.S279782] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Ho SY, Hsu CY, Liu PH, Hsia CY, Lei HJ, Huang YH, Ko CC, Su CW, Lee RC, Hou MC, Huo TI. Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver Int. 2020;40:205-214. [PMID: 31505104 DOI: 10.1111/liv.14249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
178 Chang K, Chi C, Lee R, Hou M, Huang Y, Lee I. Efficacy and predictors of survival in patients with solitary hepatocellular carcinoma larger than 5 cm undergoing transarterial chemoembolization. Adv in Digestive Med. [DOI: 10.1002/aid2.13278] [Reference Citation Analysis]
179 Zhong BY, Tang HH, Wang WS, Shen J, Zhang S, Li WC, Yin Y, Yang J, Liu F, Ni CF, Zhao JB, Zhu XL. Performance of artificial intelligence for prognostic prediction with the albumin-bilirubin and platelet-albumin-bilirubin for cirrhotic patients with acute variceal bleeding undergoing early transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2021;33:e153-60. [PMID: 33177378 DOI: 10.1097/MEG.0000000000001989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Ho SY, Hsu CY, Liu PH, Ko CC, Huang YH, Su CW, Lee RC, Hou MC, Huo TI. Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers (Basel) 2020;12:E1130. [PMID: 32366000 DOI: 10.3390/cancers12051130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
181 Wu B, Hu X, Jin H, Zhou L, Zhang D, Man Z, Wang Y, Yang S, Pang Q, Liu H, Cui P. Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery: A retrospective observational study. Medicine (Baltimore) 2019;98:e17394. [PMID: 31651841 DOI: 10.1097/MD.0000000000017394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Johnson PJ, Pinato DJ, Kalyuzhnyy A, Toyoda H. Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. J Clin Oncol 2022;:JCO2102373. [PMID: 35344390 DOI: 10.1200/JCO.21.02373] [Reference Citation Analysis]
183 Huang F, Gao J. Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. World J Gastroenterol 2020; 26(7): 749-758 [PMID: 32116422 DOI: 10.3748/wjg.v26.i7.749] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]